Appendix 5: Follow-up Stakeholder Interview Guide (tool 4)

Introduction

Introduction of the researcher(s)

- Name & function of researcher
- Share researcher's contact details (e.g. business card)
- In case of 2 researchers: one asking questions (mainly) and one/both taking notes

Introduction of SCUBY

- SCUBY is a 4-year research project on the scaling up of integrated care for diabetes
 and hypertension through co-creation with key stakeholders, such as you ... We are
 studying the scaling up of integrated care for diabetes and hypertension, with special
 attention to vulnerable people.
- The aim of this research is to engage with key stakeholders at all levels, to identify
 opportunities and barriers to integrated chronic care at the macro level, to implement
 and support best practices on a larger scale.
- Focus on integrated chronic care, diabetes, hypertension & vulnerable groups (key terms)

Explain purpose and the intent of the interview:

- Thank you for taking the time to provide your valuable feedback relating to the Policy
 Dialogue you recently attended in the context of the EU-funded SCUBY project (2019
 2022), developing and implementing a scale-up roadmap for chronic diseases
 (specifically for diabetes type 2 and hypertension).
- **To evaluate** the effectiveness and relevance of the Policy Dialogues and consultations with experts, we kindly ask for your participation in this (follow-up) interview. Your insights and comments will help shape and strengthen future Policy Dialogues.
- Duration of interview: max 60 min
- Ensure anonymity and confidentiality
- Questions?

Informed consent

• Ask (to sign) the informed consent and permission to record the interview

Outline of interview (topics to cover)

- Policy dialogue
- Roadmap development
- Stakeholder engagement (attributes)
- · Remarks and conclusion

Policy dialogue

- 1. What was your role and contribution in the Policy Dialogue? How was your experience?
- 2. Were the topics under discussion in the Policy Dialogue relevant (high priority) to you?
- 3. Was the **evidence** provided and discussed in the Policy Dialogue relevant and interesting to you? Can you use it and how?
- 4. How important do you think representation is in Policy Dialogues? Were certain groups not represented? What do you think are the benefits of a small vs big group in a Policy Dialogue?

- 5. How would you describe the collaboration between stakeholders in the Policy Dialogue? Have you collaborated before with some of these participating stakeholders? With who (not)?
- 6. Was a **consensus** reached on an action plan? If yes, consensus on what? And how was it reached?
- 7. To policy makers: what do you think is needed in order to implement the discussed proposal? What is your role/contribution in the scale-up of this strategy? To other stakeholders: Do you think policy-makers will implement the discussed proposal? Why (not)? What is your role/contribution in the scale-up of this strategy? Specify type of political commitment (expressive/financial/institutional (i.e. policy))? [will to implement]
- 8. How has **COVID** influenced political will towards NCD/integrated care? How, positively? How, negatively?
- 9. In your opinion, what do you think worked well and what **could be improved** from this meeting?

Roadmap

- 10. How **acceptable** do you think is this action/strategy/roadmap element [specify; e.g. training/group education programme/data monitoring] to the beneficiary (provider/patient)?
- 11. Can you please comment on both the **relevance** and the **feasibility** of the proposals, actions or strategies discussed/shared/agreed upon in the policy dialogue? (as one might be highly important but not a feasible action, or vice versa)
- 12. [Context] What do you see are (financial/political/operational) barriers that might hinder the implementation and scale-up of discussed proposals/actions/strategies in your National Policies?
- 13. [Adaptation/plasticity] Are changes to the roadmap or specific roadmap elements [specify] necessary? Which?
- 14. [**Costs**] What do you think are the costs related to this roadmap action/strategy [*specify*] and its implementation?
- 15. [later stage] Have discussed proposals and solutions led to **institutionalisation** (already become part of the healthcare system)? Why and how? [scale-up dimension of integration]
- 16. [later stage] Have discussed proposals and solutions led to diversification, the **expansion** [scale-up dimension] of the ICP? Why and how?
- 17. [later stage] Have discussed proposals and solutions led to increased population or geographical **coverage** [scale-up dimension]? Why and how?

Concluding remarks

Additional comments

Do you have any additional remarks?

Thank

 Thank your time to participate in this interview. We truly value the information you have provided. Your responses will contribute to our analysis and help us to improve policy dialogues and scale-up in the future.

Share SCUBY brochure at the end.